U.S. lawmakers have been busy writing to government agencies demanding answers and explanations on a range of issues, including drug shortages, gain-of-function research and thickets of duplicative patents that extend patent protection well beyond 20 years for some prescription drugs.
Research at Bristol Myers Squibb Co. has led to the development of [11]-carbon-labeled compounds targeting Bruton tyrosine kinase (BTK) as positron emission tomography (PET) imaging agents for the diagnosis of multiple sclerosis.
2,4-Dihydro-3h-1,2,4-triazol-3-one P2X7 receptor antagonists have been reported in an Axxam SpA patent as potentially useful for the treatment of cognitive, eye, gastrointestinal, genitourinary and psychiatric disorders, chronic pain, neuropathic pain and neurodegeneration.
Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have patented GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
A recent Shenzhen Salubris Pharmaceuticals Co. Ltd. patent describes prodrugs of atrasentan that act as endothelin ETA receptor antagonists. As such, they are reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, hypertension and IgA nephropathy.
Spark Biopharma Inc. has prepared and tested stimulator of interferon genes protein (STING; TMEM173) agonists that are reported to be useful for the treatment of cancer.
Mitogen-activated protein kinase kinase kinase 13 (MAP3K13; LZK) inhibitors reported to be useful for the treatment of cancer have been described in a recent U.S. Department of Health and Human Services patent.
Research at KHR Biotec GmbH has led to the development of eukaryotic initiation factor 4A (elF4A) and GTPase mutant inhibitors potentially useful for the treatment of cancer, craniofacial syndrome and neurofibromatosis type I.
RSS